COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi gains EU approval for Cenrifki (tolebrutinib) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses, based on phase 3 studies. Cenrifki addresses SPMS disability progression -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation approved in Japan for multiple myeloma patients, offering a convenient treatment option via OBI administration and manual injection -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple
Sanofi obtient l'approbation japonaise pour Sarclisa SC, traitement sous-cutané du myélome multiple, offrant commodité et efficacité. Possibilité d'administration via injecteur portable -
-
